Azenta, Inc. (BRKS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151504,
    "name": "Azenta, Inc.",
    "stock_name": "Azenta, Inc.",
    "full_name": "Azenta, Inc.",
    "name_url": "stocks-analysis/azenta-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "35.10",
    "chg": -0.05,
    "chgp": "-0.14%",
    "dir": -1,
    "prev_price": "35.15",
    "mcapval": "1,747.62",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US1143401024",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.44 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/azenta-inc-1151504-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Azenta, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-azenta-inc-overvalued-or-undervalued-3728310",
        "imagepath": "",
        "date": "2025-11-25 11:13:48",
        "description": "As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. Despite this positive shift, the company appears to be overvalued based on its current financial metrics. The Price to Book Value stands at 1.00, while the EV to EBITDA is notably high at 38.38, suggesting that investors are paying a premium relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the ROCE is negative at -2.84%, reflecting inefficiencies in generating returns from capital employed.\n\nIn comparison to its peers, Azenta's valuation metrics are concerning; for instance, Encompass Health Corp. has a more favorable EV to EBITDA of 12.89, while The Ensign Group, Inc. shows a P/E ratio of 32.46, indicating better market positioning. Furthermore, Azenta's stock has underperformed relative to the S&P 500 over mu..."
      },
      {
        "title": "Azenta, Inc. Hits Day High with 16.3% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/azenta-inc-hits-day-high-with-163-surge-in-stock-price-3726107",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AzentaInc_priceRelatedfactors_3726107.png",
        "date": "2025-11-24 16:42:31",
        "description": "Azenta, Inc. experienced a notable stock surge today, gaining 16.3% and reaching an intraday high. Over the past week, it has outperformed the S&P 500, despite a longer-term decline. The company reported strong operating cash flow, but faces challenges with negative operating profits and declining net sales."
      },
      {
        "title": "Azenta, Inc. Opens with 13.33% Gain, Outperforming S&P 500's 0.98% Rise",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/azenta-inc-opens-with-1333-gain-outperforming-sp-500s-098-rise-3726095",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AzentaInc_gapup_3726095.png",
        "date": "2025-11-24 16:29:21",
        "description": "Azenta, Inc. experienced a significant one-day stock increase, contrasting with the S&P 500's modest rise. While the company has shown resilience over the past month, it faces long-term challenges, including declining net sales and operating profit. Institutional holdings remain strong, indicating investor confidence amid ongoing performance scrutiny."
      },
      {
        "title": "Azenta, Inc. Experiences Revision in Its Stock Evaluation Amid Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/azenta-inc-changes-valuation-grade-from-risky-to-attractive-amid-price-increase-3726011",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AzentaInc_valuationdot_3726011.png",
        "date": "2025-11-24 15:26:00",
        "description": "Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, reflected in its negative P/E ratio and low returns on capital. Compared to peers, its valuation metrics suggest a precarious position, with significant stock volatility and a negative year-to-date return amid a stronger market backdrop."
      },
      {
        "title": "Is Azenta, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-azenta-inc-overvalued-or-undervalued-3724408",
        "imagepath": "",
        "date": "2025-11-24 11:15:04",
        "description": "As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a more favorable outlook. The company appears to be undervalued, particularly when considering its Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, which suggest that the market may not fully recognize its potential. Additionally, the EV to EBITDA ratio stands at 38.38, reflecting a significant disparity compared to peers.\n\nIn comparison to its industry peers, Azenta, Inc. has a notably high EV to EBITDA ratio, with Encompass Health Corp. at 12.89 and The Ensign Group, Inc. at 21.10, both of which are more attractive valuations. Furthermore, while Azenta is currently loss-making with a P/E ratio not applicable, it is essential to note that its return metrics, such as ROCE at -2.84% and ROE at -1.39%, indicate operational challenges. Despite these challenges, the stock's recent performance..."
      },
      {
        "title": "Is Azenta, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-azenta-inc-overvalued-or-undervalued-3723301",
        "imagepath": "",
        "date": "2025-11-23 11:09:18",
        "description": "As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive. The company appears to be undervalued, particularly given its current Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, which suggests potential for growth relative to its market price. In comparison to its peers, Azenta's EV to EBITDA ratio stands at 38.38, which is significantly higher than Encompass Health Corp.'s 12.89 and The Ensign Group, Inc.'s 21.10, indicating that while it may be undervalued, it is still facing challenges in profitability.\n\nDespite the attractive valuation grade, Azenta has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -30.22% compared to the S&P 500's 12.26%. This trend continues over longer time frames, with a 5-year return of -48.06% against the S&P 500's 85.61%, highlighting the need for caution despite the improved valuation ou..."
      },
      {
        "title": "Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/azenta-inc-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-stock-decline-3686148",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AzentaInc_technicaldot_3686148.png",
        "date": "2025-11-10 15:20:16",
        "description": "Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $29.55. Despite some weekly bullish indicators, the overall performance has lagged behind the S&P 500, reflecting challenges in the competitive market landscape."
      },
      {
        "title": "Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/azenta-inc-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-stock-volatility-3619750",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AzentaInc_technicaldot_3619750.png",
        "date": "2025-10-14 15:42:37",
        "description": "Azenta, Inc., a small-cap company in the Pharmaceuticals and Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $30.52. The stock has underperformed compared to the S&P 500, declining significantly over the past year and year-to-date, reflecting challenges in the competitive market."
      },
      {
        "title": "Is Azenta, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-azenta-inc-technically-bullish-or-bearish-3612735",
        "imagepath": "",
        "date": "2025-10-12 11:21:50",
        "description": "As of 10 October 2025, the technical trend for Azenta, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the weekly KST being bearish. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, which adds to the mixed signals. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, further supporting the bearish outlook. \n\nIn terms of performance, Azenta has underperformed the S&P 500 across multiple periods, with a year-to-date return of -40.38% compared to the S&P 500's 11.41%, and a 1-year return of -32.86% versus the S&P 500's 13.36%...."
      }
    ],
    "total": 17,
    "sid": "1151504",
    "stock_news_url": "https://www.marketsmojo.com/news/azenta-inc-1151504"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Azenta, Inc. overvalued or undervalued?

2025-11-25 11:13:48

As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a significant improvement in its perceived value. Despite this positive shift, the company appears to be overvalued based on its current financial metrics. The Price to Book Value stands at 1.00, while the EV to EBITDA is notably high at 38.38, suggesting that investors are paying a premium relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the ROCE is negative at -2.84%, reflecting inefficiencies in generating returns from capital employed. In comparison to its peers, Azenta's valuation metrics are concerning; for instance, Encompass Health Corp. has a more favorable EV to EBITDA of 12.89, while The Ensign Group, Inc. shows a P/E ratio of 32.46, indicating better market positioning. Furthermore, Azenta's stock has underperformed relative to the S&P 500 over mu...

Azenta, Inc. Hits Day High with 16.3% Surge in Stock Price

2025-11-24 16:42:31

Azenta, Inc. experienced a notable stock surge today, gaining 16.3% and reaching an intraday high. Over the past week, it has outperformed the S&P 500, despite a longer-term decline. The company reported strong operating cash flow, but faces challenges with negative operating profits and declining net sales.

Azenta, Inc. Opens with 13.33% Gain, Outperforming S&P 500's 0.98% Rise

2025-11-24 16:29:21

Azenta, Inc. experienced a significant one-day stock increase, contrasting with the S&P 500's modest rise. While the company has shown resilience over the past month, it faces long-term challenges, including declining net sales and operating profit. Institutional holdings remain strong, indicating investor confidence amid ongoing performance scrutiny.

Azenta, Inc. Experiences Revision in Its Stock Evaluation Amid Challenging Market Conditions

2025-11-24 15:26:00

Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, is facing financial challenges, reflected in its negative P/E ratio and low returns on capital. Compared to peers, its valuation metrics suggest a precarious position, with significant stock volatility and a negative year-to-date return amid a stronger market backdrop.

Is Azenta, Inc. overvalued or undervalued?

2025-11-24 11:15:04

As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive, indicating a more favorable outlook. The company appears to be undervalued, particularly when considering its Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, which suggest that the market may not fully recognize its potential. Additionally, the EV to EBITDA ratio stands at 38.38, reflecting a significant disparity compared to peers. In comparison to its industry peers, Azenta, Inc. has a notably high EV to EBITDA ratio, with Encompass Health Corp. at 12.89 and The Ensign Group, Inc. at 21.10, both of which are more attractive valuations. Furthermore, while Azenta is currently loss-making with a P/E ratio not applicable, it is essential to note that its return metrics, such as ROCE at -2.84% and ROE at -1.39%, indicate operational challenges. Despite these challenges, the stock's recent performance...

Is Azenta, Inc. overvalued or undervalued?

2025-11-23 11:09:18

As of 21 November 2025, the valuation grade for Azenta, Inc. has moved from risky to attractive. The company appears to be undervalued, particularly given its current Price to Book Value of 1.00 and an EV to Sales ratio of 2.17, which suggests potential for growth relative to its market price. In comparison to its peers, Azenta's EV to EBITDA ratio stands at 38.38, which is significantly higher than Encompass Health Corp.'s 12.89 and The Ensign Group, Inc.'s 21.10, indicating that while it may be undervalued, it is still facing challenges in profitability. Despite the attractive valuation grade, Azenta has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -30.22% compared to the S&P 500's 12.26%. This trend continues over longer time frames, with a 5-year return of -48.06% against the S&P 500's 85.61%, highlighting the need for caution despite the improved valuation ou...

Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-11-10 15:20:16

Azenta, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $29.55. Despite some weekly bullish indicators, the overall performance has lagged behind the S&P 500, reflecting challenges in the competitive market landscape.

Azenta, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility

2025-10-14 15:42:37

Azenta, Inc., a small-cap company in the Pharmaceuticals and Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $30.52. The stock has underperformed compared to the S&P 500, declining significantly over the past year and year-to-date, reflecting challenges in the competitive market.

Is Azenta, Inc. technically bullish or bearish?

2025-10-12 11:21:50

As of 10 October 2025, the technical trend for Azenta, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the weekly KST being bearish. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, which adds to the mixed signals. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, further supporting the bearish outlook. In terms of performance, Azenta has underperformed the S&P 500 across multiple periods, with a year-to-date return of -40.38% compared to the S&P 500's 11.41%, and a 1-year return of -32.86% versus the S&P 500's 13.36%....

View All News